培门冬酶联合吉西他滨、顺铂和地塞米松方案治疗NK/T细胞淋巴瘤的疗效及安全性

The efficacy and safety of pegaspargase combined with gemcitabine,cisplatin and dexamethasone in the treatment of NK/T cell lymphoma

目的探究培门冬酶联合吉西他滨、顺铂和地塞米松方案治疗NK/T细胞淋巴瘤的治疗效果及安全性。方法选取NK/T细胞淋巴瘤患者50例,采用随机数字表法将患者随机分为观察组与对照组,每组各25例。观察组给予培门冬酶联合吉西他滨、顺铂和地塞米松方案治疗,对照组给予CHOPL方案治疗,比较两组患者的临床疗效及不良反应发生情况,并对患者2年内生存情况进行分析。结果治疗后,观察组患者的完全缓解率高于对照组患者(P﹤0.05);观察组与对照组患者的治疗总有效率比较,差异无统计学意义(P﹥0.05);观察组患者的消化道反应、高血糖和过敏反应发生率均低于对照组患者(P﹤0.05);观察组患者2年内中位无进展生存时间(PFS)、中位总生存时间(OS)均明显长于对照组患者(P﹤0.01)。结论培门冬酶联合吉西他滨、顺铂和地塞米松方案治疗NK/T细胞淋巴瘤具有较好的疗效,且不良反应少,安全性高,值得在临床上推广使用。

Objective To explore the efficacy and safety of pegaspargase in combination with gemcitabine, cisplatin and dexamethasone regimen for NK/T cell lymphoma. Method 50 cases of NK/T-cell lymphoma patients were enrolled in the study, and were randomized as study group or control group as per a random number table, with 25 cases in each, respectively. The study group was treated with pegaspargase plus gemcitabine, cisplatin and dexamethasone, while pa-tients in control group were administered with CHOPL regimen, and then the clinical efficacy and incidence of adverse re-actions of the two groups were compared, and the 2-year survival of all patients were analyzed. Result After treatment, the study group had significantly higher complete response rate than the control group （P〈0.05）, but the overall response rate of the two groups were similar （P〉0.05）;The incidence of digestive tract reaction, hyperglycemia and allergic reac-tion were lower in study group than that in control group （P〈0.05）;And the median PFS and median OS of study group were better than those of control group （P〈0.01）. Conclusion Pegaspargase in combination with gemcitabine, cisplatin and dexamethasone is effective in treating the NK/T cell lymphoma, with minor adverse reactions and superior safety, and is a clinically practicable regimen.